Russia's "Sputnik-V" COVID-19 vaccine produced an antibody response in all participants in early-stage trials, according to results published on Friday by The Lancet medical journal that were hailed by Moscow as an answer to its critics.
The results of the two trials, conducted in June-July this year and involving 76 participants, showed 100% of participants developing antibodies to the new coronavirus and no serious side effects, The Lancet said.
Follow Israel Hayom on Facebook and Twitter
Russia licensed the two-shot jab for domestic use in August, becoming the first country to do so before any data had been published or a large-scale trial began.
